<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BETHKIS- tobramycin solution </strong><br>Chiesi USA, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <span class="Bold">BETHKIS</span> safely and effectively.  See full prescribing information for <span class="Bold">BETHKIS</span>.<br><br><span class="Bold">BETHKIS<span class="Sup">®</span> (Tobramycin Inhalation Solution)<br></span>Initial U.S. Approval: 1980</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">BETHKIS is an inhaled aminoglycoside antibacterial indicated for the management of <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients with <span class="Italics">Pseudomonas aeruginosa</span>. (<a href="#LINK_1c79114f-7893-4146-ada7-2c8d8d3e116c">1</a>)  Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in one second (FEV<span class="Sub">1</span>) less than 40% or greater than 80% predicted, or patients colonized with <span class="Italics">Burkholderia cepacia</span>. (<a href="#LINK_1c79114f-7893-4146-ada7-2c8d8d3e116c">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Administer the entire contents of one ampule twice daily by oral inhalation in repeated cycles of 28 days on drug, followed by 28 days off drug. (<a href="#LINK_5e8db2d5-36fa-4a59-ae7a-456255eeaabe">2.1</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">A clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution for oral inhalation in a single-use ampule containing 300 mg tobramycin. (<a href="#LINK_7b18b440-9414-4355-82b1-726b6fb6de67">16</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">BETHKIS is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any aminoglycoside. (<a href="#LINK_625ed2aa-5ef3-46bc-b2d7-fdd8cb774eb3">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Caution should be exercised when prescribing BETHKIS to patients with known or suspected auditory, vestibular, renal, or neuromuscular dysfunction. (<a href="#LINK_5669d95e-622d-406c-907c-db8567498585">5.1</a>, <a href="#LINK_4d269a6b-8524-4fbd-b0eb-1a909dee5968">5.2</a>, <a href="#LINK_5182e959-8b51-4715-8cbc-e10feae8b621">5.3</a> and <a href="#LINK_33f55eff-c087-463c-b97f-58c2f6b48361">5.5</a>)</li>
<li>Aminoglycoside may aggravate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> because of a potential curare-like effect on neuromuscular function. (<a href="#LINK_5182e959-8b51-4715-8cbc-e10feae8b621">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> can occur with inhalation of BETHKIS. (<a href="#LINK_264980b4-c578-4153-9716-0b7080c1009b">5.4</a>)</li>
<li>Audiograms, serum concentration, and renal function should be monitored as appropriate. (<a href="#LINK_4d269a6b-8524-4fbd-b0eb-1a909dee5968">5.2</a> and <a href="#LINK_33f55eff-c087-463c-b97f-58c2f6b48361">5.5</a>)</li>
<li>Fetal harm can occur when aminoglycosides are administered to a pregnant woman. Apprise women of the potential hazard to the fetus. (<a href="#LINK_33f55eff-c087-463c-b97f-58c2f6b48361">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are <span class="product-label-link" type="condition" conceptid="4261798" conceptname="Decreased forced expiratory volume">forced expiratory volume decreased</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>, <span class="product-label-link" type="condition" conceptid="4013526" conceptname="ESR raised">red blood cell sedimentation rate increased</span>, and <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>. (<a href="#LINK_055398af-794e-477e-a456-0d60531fe8e9">6.1</a>)<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA, Inc. at 1-888- 661-9260 or FDA at 1-800-FDA-1088 or <span class="Underline"><span class="Italics">www.fda.gov/medwatch</span></span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk">
<li>Concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic or ototoxic potential should be avoided. (<a href="#LINK_167c3f2c-5203-4f5a-9548-41440e03aea9">7.1</a>)</li>
<li>BETHKIS should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol. (<a href="#LINK_70a8998a-1be0-4fd2-a838-04f6010c268c">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li>Aminoglycosides can cause fetal harm when administered to a pregnant woman. (<a href="#LINK_077c19cc-44a6-4bb4-8715-388b0c7057a3">8.1</a>)</li>
<li>Nursing mothers: discontinue drug or nursing, taking into consideration the importance of the drug to a mother. (<a href="#LINK_3c23d400-f20a-484f-87e6-c1781e77d75d">8.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 3/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Neuromuscular Disorders</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Laboratory Tests</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Use in Pregnancy</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Drugs with Neurotoxic or Ototoxic Potential</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Ethacrynic Acid, Furosemide, Urea, or Mannitol</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Risks Associated with Aminoglycosides</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Laboratory Tests</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 Pregnancy</a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Storage Instructions</a></h2>
<h2><a href="#section-16.7" class="toc">17.7 Additional Information</a></h2>
<h2><a href="#section-17.1" class="toc">Patient Information</a></h2>
<h2><a href="#section-17.2" class="toc">Instructions for Use</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_1c79114f-7893-4146-ada7-2c8d8d3e116c"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">BETHKIS is indicated for the management of <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients with <span class="Italics">Pseudomonas aeruginosa</span>.  Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV<span class="Sub">1</span> less than 40% or greater than 80% predicted, or patients colonized with <span class="Italics">Burkholderia cepacia</span>.<span class="Italics"> </span>(<span class="Italics">See CLINICAL STUDIES (<a href="#LINK_9a63955b-45d4-45e1-8afc-a03d52489fda">14</a>)</span>)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_d37d18d8-9848-469e-ab49-e7bc19098332"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5e8db2d5-36fa-4a59-ae7a-456255eeaabe"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Dosing Information</h2>
<p class="First">The recommended dosage for patients six years of age and older is to administer one single-use ampule (300 mg/4 mL) twice daily by oral inhalation in repeated cycles of 28 days on drug, followed by 28 days off drug. The doses should be taken as close to 12 hours apart as possible and not less than 6 hours apart.</p>
<p>The 300 mg/4 mL dose of BETHKIS is the same for patients regardless of age or weight. BETHKIS has not been studied in patients less than six years old.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9f015fc1-777f-452b-bbdf-5ec57da11795"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Administration</h2>
<p class="First">BETHKIS is administered by oral inhalation.  Do not use by any other route.</p>
<p>BETHKIS is administered by inhalation using a hand‑held PARI LC PLUS Reusable Nebulizer with a PARI Vios Air compressor over an approximately 15 minute period and until sputtering from the output of the nebulizer has occurred for at least one minute.</p>
<p>Further patient instructions on how to administer BETHKIS are provided in the <span class="Italics">PATIENT COUNSELING INFORMATION (<a href="#LINK_d403d4ff-0480-48fb-8e10-594b0afd88bf">17</a></span>) and the <span class="Italics">PATIENT’S INSTRUCTIONS FOR USE</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_f6dcd32d-9baf-411b-a55f-173ce421cdec"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">4 mL single-use ampules containing 300 mg of tobramycin.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_625ed2aa-5ef3-46bc-b2d7-fdd8cb774eb3"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">BETHKIS is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any aminoglycoside.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_2128b639-27a3-47cd-83b9-a40c2006c22b"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5669d95e-622d-406c-907c-db8567498585"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span></h2>
<p class="First">Caution should be exercised when prescribing BETHKIS to patients with known or suspected auditory or vestibular dysfunction.</p>
<p>Findings related to <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> as measured by audiometric evaluations and auditory adverse event reports were similar between BETHKIS and placebo in controlled clinical trials. <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span> was reported in two (1.1%) BETHKIS-treated patients and in one (0.9%) placebo-treated patient during clinical studies.  Additionally, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, both of which may be manifestations of vestibular forms of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, were observed in similar numbers of BETHKIS- and placebo-treated patients.  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> occurred in two (1.1%) BETHKIS-treated patients and one (0.9%) placebo-treated patient and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> occurred in two (1.1%) BETHKIS‑treated patients versus no placebo patients in clinical studies. None of the BETHKIS patients discontinued their therapy due to <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> may be a sentinel symptom of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>.  No reports of <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> occurred in patients during clinical studies with BETHKIS, but because it has been observed with inhaled tobramycin solutions, onset of this symptom warrants caution.  <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>, manifested as both auditory and vestibular toxicity, has been reported with parenteral aminoglycosides.  Vestibular toxicity may be manifested by <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4d269a6b-8524-4fbd-b0eb-1a909dee5968"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></h2>
<p class="First">Caution should be exercised when prescribing BETHKIS to patients with known or suspected renal dysfunction. </p>
<p><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> was not seen during BETHKIS clinical studies but has been associated with aminoglycosides as a class. If <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> occurs in a patient receiving BETHKIS, therapy should be discontinued until serum concentrations <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below 2 mcg/mL.</p>
<p>Twenty-six (14%) BETHKIS patients and 15 (13%) placebo patients had increases in serum creatinine of at least 50% over baseline. Follow-up values were obtained for 17 of the 26 BETHKIS patients, all of which decreased to serum creatinine values that were within normal laboratory ranges.  Patients who experience an increase in serum creatinine during treatment with BETHKIS should have their renal function closely monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5182e959-8b51-4715-8cbc-e10feae8b621"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Neuromuscular Disorders</h2>
<p class="First">BETHKIS should be used cautiously in patients with muscular disorders, such as <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or Parkinson’s disease, since aminoglycosides may aggravate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> because of a potential curare-like effect on neuromuscular function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_264980b4-c578-4153-9716-0b7080c1009b"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> can occur with inhalation of tobramycin. In clinical studies with BETHKIS, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> was observed in one (0.5%) BETHKIS-treated patient and in no placebo-treated patients. <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span> occurred in ten (5%) BETHKIS-treated patients and four (4%) placebo-treated patients. <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> should be treated as medically appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_33f55eff-c087-463c-b97f-58c2f6b48361"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Laboratory Tests</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_107d9705-d28b-4266-a7d6-ef1ecb119c8d"></a><a name="section-5.5.1"></a><p></p>
<h3><span class="Bold">5.5.1	Audiograms</span></h3>
<p class="First">Clinical studies of inhaled tobramycin solutions did not identify <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> using audiometric tests which evaluated hearing up to 8000 Hz. Physicians should consider an audiogram for patients who show any evidence of auditory dysfunction, or who are at increased risk for auditory dysfunction.<span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> may be a sentinel symptom of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, and therefore the onset of this symptom warrants caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ae78a0a4-9d24-4cbf-84ca-d6b12d9a5aaf"></a><a name="section-5.5.2"></a><p></p>
<h3><span class="Bold">5.5.2	Serum Concentrations</span></h3>
<p class="First">In patients with normal renal function treated with BETHKIS, serum tobramycin concentrations range from approximately 0.06-1.89 mcg/mL one hour after dose administration and do not require routine monitoring. Serum concentrations of tobramycin in patients with renal dysfunction or patients treated with concomitant parenteral tobramycin should be monitored at the discretion of the treating physician. (<span class="Italics">See <a href="#LINK_4af92dc4-3fc8-40aa-bcc8-11fc4e780d65">12.3</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0bc8c351-1f5f-4280-ba4d-43ede3e1ddd5"></a><a name="section-5.5.3"></a><p></p>
<h3><span class="Bold">5.5.3	Renal Function</span></h3>
<p class="First">The clinical studies of BETHKIS did not reveal any imbalance in the percentage of patients who experienced at least a 50% rise in serum creatinine from baseline in either the BETHKIS group (n=26, 14%) or the placebo group (n=15, 13%). Laboratory tests of urine and renal function should be conducted at the discretion of the treating physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b8b52d6c-1fd5-4a9d-8d6f-1490af4af734"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Use in Pregnancy</h2>
<p class="First">Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides cross the placenta, and streptomycin has been associated with several reports of total irreversible, bilateral <span class="product-label-link" type="condition" conceptid="4318712" conceptname="Congenital deafness">congenital deafness</span> in pediatric patients exposed <span class="Italics">in utero</span>. Patients who use BETHKIS during pregnancy, or become pregnant while taking BETHKIS should be apprised of the potential hazard to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_3acca151-e958-41d1-9c1a-a871f0763b8b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_055398af-794e-477e-a456-0d60531fe8e9"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of drugs cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to BETHKIS in two placebo-controlled studies in 305 <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients.  Patients receiving BETHKIS ranged in age from 6 to 31 years. </p>
<p>In Study 1, an eight week study, 29 patients received BETHKIS versus 30 patients who received placebo for a total of four weeks on drug and four weeks off drug.  All patients were ≤ 30 years of age (mean age 12.6 years) and 46% were females. 52.5% of patients were 6 to 12 years of age while 30.5% of patients were 13-17 years old. Only 16.5% of patients were adults (&gt; 17 years old). Eighty percent (80%) of patients were chronically colonized with <span class="Italics">Pseudomonas aeruginosa</span> while 20.3% of patients were initially or intermittently colonized with <span class="Italics">Pseudomonas aeruginosa</span> during the study. </p>
<p>More patients in the placebo group discontinued/dropped out of Study 1 than in the BETHKIS group (23% [7/30] vs 3.4% [1/29], respectively). Five patients in the placebo group compared to none in the BETHKIS group discontinued/dropped out because of treatment-emergent adverse events (TEAEs) such as pulmonary exacerbations and <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span>. </p>
<p>In Study 2, a 24 week study, 161 patients received BETHKIS versus 85 patients who received placebo in alternating four week on-off cycles for three cycles. All patients were ≤ 46 years of age (mean age 14.8 years) and 45% were females. 41% of patients were 6-12 years old while 29% of patients were 13-17 years old. Only 30% were adults (&gt;17 years). Eighty-seven percent (87%) of patients were chronically colonized with <span class="Italics">P. aeruginosa</span>. Only 13% were either initially or intermittently colonized with <span class="Italics">P. aeruginosa</span> during the study.</p>
<p>More patients in the placebo group discontinued/dropped out of Study 2 than in the BETHKIS group (9.4% [8/85] vs 4.3% [7/161], respectively). Of these, 3 patients in the BETHKIS group (1.9%) compared to 2 patients in the placebo group (2.4%) withdrew due to a TEAE. The most common TEAEs causing patients to discontinue from the study drug are respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>.</p>
<p>The most common adverse experiences reported were <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span>, consistent with the underlying disease in the patient population being evaluated and these were similarly distributed between both BETHKIS- and placebo-treated patients. The following adverse reactions were reported in at least 5% of Bethkis-treated patients and at rates ≥ 2% more common compared to the placebo-treated patients: decreased forced expiratory volume, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>, <span class="product-label-link" type="condition" conceptid="4013526" conceptname="ESR raised">red blood cell sedimentation rate increased</span>, and <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span> (Table 1).<span class="Bold"><br></span></p>
<table>
<caption><span>Table 1: Patients with Selected Treatment-Emergent Adverse Reactions Occurring in ≥ 2% of BETHKIS Patients</span></caption>
<col width="53%">
<col width="30%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"><span class="Bold">Adverse Reactions</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"><span class="Bold">BETHKIS<br>N=190<br>(%)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First"><span class="Bold">Placebo<br>N=115<br>(%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"> <p class="First"><span class="product-label-link" type="condition" conceptid="4261798" conceptname="Decreased forced expiratory volume">Forced expiratory volume decreased</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">59 (31%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">33 (29%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"> <p class="First"><span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">36 (19%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">18 (16%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"> <p class="First"><span class="product-label-link" type="condition" conceptid="4013526" conceptname="ESR raised">Red blood cell sedimentation rate increased</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">16 (8%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">6 (5%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"> <p class="First"><span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">Dysphonia</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">11 (6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">2 (2%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <p class="First"><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">10 (5%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">4 (4%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <p class="First"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">6 (3%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <p class="First">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">5 (3%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">2 (2%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">5 (3%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1 (1%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <p class="First"><span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">4 (2%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (2%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1 (1%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <p class="First"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (2%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> <p class="First"><span class="product-label-link" type="condition" conceptid="4037191" conceptname="Increased immunoglobulin">Immunoglobulins increased</span> </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">3 (2%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">0</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e85da920-64a6-4791-bb6d-3cf1764b2c9d"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">In postmarketing experience, some patients receiving inhaled tobramycin have reported <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>. Some of these reports occurred in patients with previous or concomitant treatment with systemic aminoglycosides. Patients with <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> frequently reported <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> (<span class="Italics">see WARNINGS AND PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> (<a href="#LINK_5669d95e-622d-406c-907c-db8567498585">5.1</a>)</span>).</p>
<p>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_4d586db2-a0c1-4f40-a473-5545c1d0797c"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_167c3f2c-5203-4f5a-9548-41440e03aea9"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Drugs with Neurotoxic or Ototoxic Potential</h2>
<p class="First">Concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic or ototoxic potential should be avoided. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_70a8998a-1be0-4fd2-a838-04f6010c268c"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Ethacrynic Acid, Furosemide, Urea, or Mannitol</h2>
<p class="First">Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.  Therefore, BETHKIS should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_0458d0c6-23b5-4a09-bebc-4c7f5797ef50"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_077c19cc-44a6-4bb4-8715-388b0c7057a3"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Teratogenic Effects-Pregnancy Category D</p>
<p>No reproduction toxicology studies have been conducted with inhaled tobramycin. However, subcutaneous administration of tobramycin at doses of 100 mg or 20 mg/kg/day during organogenesis was not teratogenic in rats or rabbits, respectively.  Subcutaneous doses of tobramycin ≥ 40mg/kg/day were severely maternally toxic to rabbits and precluded the evaluation of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.  Aminoglycosides can cause fetal harm (e.g., <span class="product-label-link" type="condition" conceptid="4318712" conceptname="Congenital deafness">congenital deafness</span>) when administered to a pregnant woman. <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> was not evaluated in offspring during nonclinical reproduction toxicity studies with tobramycin. If tobramycin is used during pregnancy, or if the patient becomes pregnant while taking tobramycin, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_4877a4d7-3af9-4331-a2cf-7a596317a6d4"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The safety and efficacy of BETHKIS have not been studied in the puerperal patient.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_3c23d400-f20a-484f-87e6-c1781e77d75d"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if tobramycin will reach sufficient concentrations after administration by inhalation to be excreted in human breast milk. Because of the potential for <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> in infants, a decision should be made whether to terminate nursing or discontinue tobramycin therapy, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_f6720f86-6bd1-4294-9a43-24d03d05c676"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of BETHKIS have not been studied in pediatric <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients under six years of age.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_86d97065-dd66-4f83-a292-7badf92f8fe0"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The safety and efficacy of BETHKIS have not been studied in adult <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients over 31 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5607c4bf-a703-437a-a459-0566c97e0e78"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Tobramycin is primarily excreted unchanged in the urine and renal function is expected to affect the exposure of tobramycin. The risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Patients with serum creatinine &gt; 2mg/dL and blood urea nitrogen (BUN) &gt; 40mg/dL have not been included in clinical studies and there are no data in this population to support a recommendation for or against dose adjustment [<span class="Italics">See</span> <span class="Italics">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_4d269a6b-8524-4fbd-b0eb-1a909dee5968">5.2</a>, <a href="#LINK_33f55eff-c087-463c-b97f-58c2f6b48361">5.5</a>)].</p>
<p>Serum concentrations of tobramycin in patients with renal dysfunction, or patients treated with concomitant parenteral tobramycin should be monitored at the discretion of the treating physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_8ee8f582-db34-4275-be29-f54309af16d9"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have been reported with BETHKIS in clinical trials.  Signs and symptoms of acute toxicity from overdosage of intravenous tobramycin might include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, loss of high-tone hearing acuity, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>.  Administration by inhalation results in low systemic bioavailability of tobramycin.  Tobramycin is not significantly absorbed following oral administration.   Tobramycin serum concentrations may be helpful in monitoring overdosage.</p>
<p>In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment. In the case of any overdosage, the possibility of drug interactions with alterations in drug disposition should be considered.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_c1940a1c-b52a-4bbd-b1a1-a79e79f81732"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">BETHKIS is a sterile, clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, non-pyrogenic, aqueous solution with pH and salinity adjusted. BETHKIS is administered by a compressed air driven reusable nebulizer. The chemical formula for tobramycin is C<span class="Sub">18</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">9</span> and the molecular weight is 467.52. Tobramycin is O‑3-amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-[2,6-diamino- 2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-L‑streptamine.</p>
<p>The structural formula for tobramycin is:</p>
<div class="Figure"><img alt="Tobramycin structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-1.jpg"></div>
<p>Each single-use 4 mL ampule of BETHKIS contains one 300 mg dose of tobramycin, with sodium chloride and sulfuric acid in water for injection. Sulfuric acid and sodium hydroxide are used to adjust the pH, as needed, to 5.0. Nitrogen is used for sparging, filling and pouching. The formulation contains no preservatives.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_1453e738-5e26-45c8-9bcd-393f6ed1fd8b"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_3e0b3f08-a8e6-419a-8e38-76215c180df4"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">BETHKIS is an antibacterial drug <span class="Italics">(see <a href="#LINK_18724566-d0f1-4471-aa72-a3511028e921">12.4</a> Microbiology</span>).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_4af92dc4-3fc8-40aa-bcc8-11fc4e780d65"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">BETHKIS contains tobramycin, a cationic polar molecule that does not readily cross epithelial membranes.<span class="Sup">1 </span>The bioavailability of BETHKIS may vary because of individual differences in nebulizer performance and airway pathology.<span class="Sup">2</span> Following administration of BETHKIS, tobramycin remains concentrated primarily in the airways.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span> Concentrations: </span>Thirty minutes after inhalation of the first 300 mg dose of BETHKIS, the maximum geometric mean concentration of tobramycin was 814 mcg/g (ranging from 23 to 2843 mcg/g) in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>. High variability of tobramycin concentration in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> was observed. Three hours after inhalation started, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> tobramycin concentrations declined to approximately 15% of those observed at 30 minutes.  After four weeks of therapy with BETHKIS average mean <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> tobramycin concentrations obtained 10 minutes following administration were 717 mcg/g.</p>
<p><span class="Italics">Elimination: </span>The elimination half-life of tobramycin from serum is approximately two hours after intravenous (IV) administration. The elimination half-life following the inhalation of BETHKIS is approximately 4.4 hours. Assuming tobramycin absorbed following inhalation behaves similarly to tobramycin following intravenous administration, systemically absorbed tobramycin is eliminated principally by glomerular filtration.  Unabsorbed tobramycin following inhalation is likely eliminated in expectorated <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_18724566-d0f1-4471-aa72-a3511028e921"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>Tobramycin, an aminoglycoside antimicrobial, acts primarily by disrupting protein synthesis in the bacterial cell which eventually leads to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the cell. Tobramycin has activity against a wide range of gram-negative bacteria including <span class="Italics">P. aeruginosa</span>.  It is bactericidal at or above the minimal inhibitory concentration (MIC) needed to inhibit growth of bacteria.</p>
<p><span class="Bold">Mechanism of Resistance</span></p>
<p>The predominant mechanism of resistance to tobramycin in <span class="Italics">P. aeruginosa</span> isolated from CF patients is impermeability and to a lesser extent enzymatic modification and other mechanisms which cumulatively lead to decreased susceptibility of <span class="Italics">P. aeruginosa </span>to tobramycin.</p>
<p><span class="Bold">Cross Resistance</span></p>
<p>Cross resistance between aminoglycosides exists but the cross resistance is variable.</p>
<p><span class="Bold">Development of Resistance</span></p>
<p>Treatment for six months with BETHKIS in one clinical trial did not affect the susceptibility of the majority of <span class="Italics">P. aeruginosa</span> isolates tested; however, increases in minimal inhibitory concentrations (MIC) were noted in some patients.  The clinical significance of this information has not been clearly established in the treatment of <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients.</p>
<p><span class="Bold">Susceptibility Testing</span></p>
<p>The clinical microbiology laboratory should provide cumulative results of the <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physicians as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
<p><span class="Bold">Susceptibility Testing Techniques</span></p>
<p><span class="Bold"><span class="Italics">Dilution Techniques</span></span></p>
<p>Quantitative methods can be used to determine the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) of tobramycin that will inhibit the growth of the bacteria being tested. The MIC provides an estimate of the susceptibility of bacteria to tobramycin. The MIC should be determined using a standardized procedure.<span class="Sup">3, 5</span> Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of tobramycin powder.</p>
<p><span class="Bold"><span class="Italics">Diffusion Techniques</span></span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations.<span class="Sup">4,5</span> This procedure uses paper disks impregnated with 10 mcg of tobramycin to test the susceptibility of bacteria to tobramycin.</p>
<p><span class="Bold">Susceptibility Test Interpretive Criteria</span></p>
<p><span class="Italics">In vitro</span> susceptibility test interpretive criteria for inhaled tobramycin have not been determined. The relation of the in vitro MIC and/or disk diffusion susceptibility test results to clinical efficacy of inhaled tobramycin against the bacteria tested should be monitored. </p>
<p><span class="Bold">Quality Control Parameters for Susceptibility Testing</span></p>
<p><span class="Italics">In vitro</span> susceptibility test quality control parameters exist for tobramycin so that laboratories that test the susceptibility of bacterial isolates to tobramycin can determine if the susceptibility test is performing correctly. Standardized dilution techniques and diffusion methods require the use of laboratory control bacteria to monitor the technical aspects of the laboratory procedures. Standard tobramycin powder should provide the following MIC and a 10 mcg tobramycin disk should produce the following zone diameters with the indicated quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> (Table 2).</p>
<table width="686px">
<caption><span>Table 2: Acceptable Quality Control Ranges for Tobramycin</span></caption>
<col width="38%">
<col width="38%">
<col width="38%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">  
<p class="First"><span class="Bold">Bacteria</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">  
<p class="First"><span class="Bold">MIC Range</span><br>(mcg/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">  
<p class="First"><span class="Bold">Disk Diffusion Zone Diameter (mm)    </span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">  
<p class="First"><span class="Italics">Pseudomonas</span> a<span class="Italics">eruginosa<br></span>ATCC 27853</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">  
<p class="First">0.25-1</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">  
<p class="First">19-25</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Other</span></p>
<p>No trends in the treatment-emergent isolation of other bacterial respiratory pathogens such as <span class="Italics">Burkholderia cepacia</span>, <span class="Italics">Stenotrophomonas maltophilia</span>, <span class="Italics">Achromobacter xylosoxidans</span>, or <span class="Italics">Staphylococcus aureus</span> were observed in clinical trials of BETHKIS relative to placebo. There was a slight increase in isolation of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="Italics">spp</span> in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> at the end of the BETHKIS treatment cycle in clinical trials.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_60d2e703-3bf9-44c6-b6de-c708c8df468f"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_d4f1f7d7-7421-40ca-bb8c-969bf995118e"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A two-year rat inhalation toxicology study to assess carcinogenic potential of an inhaled solution of tobramycin has been completed. Rats were exposed to tobramycin for up to 1.5 hours per day for 95 weeks. Serum levels of tobramycin up to 35 mcg/mL were measured in rats, 35x the average 1 mcg/mL exposure levels observed in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients in clinical trials. There was no drug-related increase in the incidence of any variety of tumors.</p>
<p>Additionally, tobramycin has been evaluated for genotoxicity in a battery of <span class="Italics">in vitro </span>and <span class="Italics">in vivo </span>tests. The Ames bacterial reversion test, conducted with five tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, failed to show a significant increase in revertants with or without metabolic activation in all <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. Tobramycin was negative in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay, did not induce chromosomal aberrations in Chinese hamster ovary cells, and was negative in the mouse micronucleus test.</p>
<p>Subcutaneous administration of up to 100 mg/kg of tobramycin did not affect mating behavior or cause impairment of fertility in male or female rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_9a63955b-45d4-45e1-8afc-a03d52489fda"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Two, double-blind, randomized, placebo-controlled, parallel group clinical studies (Study 1 and Study 2), which randomized and dosed 306 patients, were conducted in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients with <span class="Italics">P. aeruginosa</span>. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of the drug formulation used in these studies differed from the to-be-marketed product. To rely upon the efficacy and safety established in the placebo-controlled studies, an additional study was conducted as a bridge to the to-be-marketed drug. The bridging study assessed the efficacy and tolerability of aerosolized Tobramycin Inhalation Solution with <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> similar to BETHKIS over a 4-week treatment in 324 patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>. Results of this study showed that the Tobramycin Inhalation Solution in this study had similar efficacy as that seen in the placebo-controlled studies.</p>
<p>The compressors in the placebo-controlled studies and the bridging study differed from the PARI VIOS compressor to be used with BETHKIS. In vitro cascade impaction studies demonstrated that the various compressors used in the clinical trials delivered equivalent doses and respirable fractions of the to-be-marketed BETHKIS and TOBI with the marketed compressor (PARI VIOS) when used with the same nebulizer (PARI LC Plus Reusable nebulizer).</p>
<p>All subjects enrolled in both efficacy studies had baseline FEV<span class="Sub">1</span> % predicted ≥ 40% and ≤ 80% (mean baseline FEV<span class="Sub">1 </span>of 60% of predicted normal) and infected with <span class="Italics">P. aeruginosa</span>. Subjects who were less than 6 years of age, or who had a baseline creatinine of ≥ 1.5 mg/dL, or who had <span class="Italics">Burkholderia cepacia</span> isolated from <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> were excluded. A total of 190 patients, 29 in Study 1 and 161 in Study 2, received BETHKIS therapy on an outpatient basis. Of these, 55% were males and 45% were females. Eighty-two (43.2%) patients were between 6 and 12 years of age, 54 (28.4%) patients were between 13 and 17 years of age, and the remaining 54 (28.4%) patients were greater than 17 years of age. Of the patients who received BETHKIS, only 89.7% of patients in Study 1 had at least one concomitant medication, while all patients in Study 2 also received at least one concomitant medication. These concomitant medications include mucolytics, steroidal and nonsteroidal anti-inflammatory drugs, bronchodilators, rehabilitative physiotherapies and if necessary, antibiotics for <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> other than <span class="Italics">P. aeruginosa</span>.</p>
<p><span class="Bold">Study 1</span></p>
<p>Study 1 was a double-blind, single cycle study that randomized 59 patients to receive BETHKIS (n=29) or placebo (n=30) for one cycle of treatment (28 days on treatment followed by 28 days off treatment). All patients were ≤ 30 years of age (mean age 12.6 years) and 46% were females. All randomized patients were included in the primary analysis except for one patient who had missing baseline information. </p>
<p>BETHKIS significantly improved lung function compared with placebo as measured by the absolute change in FEV<span class="Sub">1 </span>% predicted from baseline to the end of Cycle 1 dosing in the primary analysis population. Treatment with BETHKIS and placebo resulted in absolute increases in FEV<span class="Sub">1 </span>% predicted of 16% and 5%, respectively (LS mean difference = 11%; 95% CI: 3, 19; p=0.003). This analysis is adjusted for the covariate of baseline FEV<span class="Sub">1</span> % predicted, using multiple imputation for missing data. Figure 1 shows the average change in FEV<span class="Sub">1 </span>% predicted over eight weeks. </p>
<p><span class="Bold">Study 2</span></p>
<p>Study 2 was a randomized, double-blind, 3-cycle, placebo-controlled trial. A total of 247 eligible patients were randomized 2:1 to receive three cycles of BETHKIS (n=161) or placebo (n=86).  As in Study 1, each cycle comprised 28 days on treatment followed by 28 days off treatment.  All patients were ≤46 years of age (mean age 14.8 years) and 44.9% were females. In this study, two randomized patients in the placebo group were not included in the primary efficacy analysis; one withdrew consent without taking any trial medication and the other withdrew due to an adverse drug reaction. </p>
<p>BETHKIS significantly improved lung function compared with placebo as measured by the absolute change in FEV<span class="Sub">1</span> % predicted from baseline to the end of Cycle 3 “ON? period.  Treatment with BETHKIS and placebo resulted in absolute increases in FEV<span class="Sub">1</span> % predicted of 7% and 1%, respectively (LS mean difference = 6%; 95% CI: 3, 10; p&lt;0.001). This analysis is adjusted for the covariate of baseline FEV<span class="Sub">1</span> % predicted, using multiple imputation for missing data. Figure 1 shows the average change in FEV<span class="Sub">1</span> % predicted over 24 weeks from Study 2.</p>
<p><span class="Bold">Figure 1: FEV<span class="Sub">1 </span>% of Predicted Normal – Absolute Change from Baseline (Adjusted mean) - ITT Population   </span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-2.jpg"></div>
<p>In Study 2, 9.9% of patients treated with BETHKIS and 24.7% of patients who received placebo had unplanned hospitalizations due to the disease. </p>
<p>Also in Study 2, 6.2% of patients treated with BETHKIS and 16.5% of placebo patients received parenteral tobramycin.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_aefdedfe-0222-4a4e-ad4a-f008e1830788"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Neu HC. Tobramycin: an overview. [Review]. J Infect Dis. 1976; Suppl 134:S3-19.</li>
<li>Weber A, Smith A, Williams-Warren J, et al. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol. 1994; 17(5):331-9.</li>
<li>Clinical and laboratory Standards Institute (CLSI) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard -9<span class="Sup">th</span> edition. CLSI document M07-A9. CLSI 940 West Valley Rd. Suite 1400, Wayne PA 19087-1898. 2012</li>
<li>CLSI Performance Standards for Antimicrobial Susceptibility Testing: 22<span class="Sup">nd</span> Informational supplement CLSI document M100-S22. CLSI 2012.</li>
<li>CLSI Performance standards for Antimicrobial Disk Susceptibility Tests: Approved standard -11<span class="Sup">th</span> ed. CLSI document M02-A11. CLSI 2012.</li>
<li>PARI Vios Aerosol Delivery System with LC Plus Nebulizer: Instructions for Use. PARI Respiratory Equipment, Inc. 2010; 310D0028 Rev A 6-10.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_7b18b440-9414-4355-82b1-726b6fb6de67"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">BETHKIS 300 mg/4 mL is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution and is available as follows: </p>
<ul class="Disk">
<li>NDC 10122-820-56: 4 mL single-use ampule (carton of 14 foil pouches each containing four ampules)</li>
<li>NDC 10122-820-28: 4 mL single-use ampule (carton of 7 foil pouches each containing four ampules)</li>
</ul>
<p><span class="Bold"><span class="Italics">Storage</span></span></p>
<p>BETHKIS should be stored under refrigeration at 36‑46 °F/2‑8 °C. Upon removal from the refrigerator, or if refrigeration is unavailable, BETHKIS pouches (opened or unopened) may be stored at room temperature (up to 77 °F/25 °C) for up to 28 days. BETHKIS should not be used beyond the expiration date stamped on the ampule when stored under refrigeration (36‑46 °F/2‑8 °C) or beyond 28 days when stored at room temperature (77 °F/25 °C). </p>
<p>BETHKIS ampules should not be exposed to intense light. BETHKIS is light sensitive; unopened ampules should be returned to the foil pouch. The solution in the ampule is colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, but may darken with age if not stored in the refrigerator; however, the color change does not indicate any change in the quality of the product as long as it is stored within the recommended storage conditions.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_d403d4ff-0480-48fb-8e10-594b0afd88bf"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">See </span><span class="Bold"><a href="#LINK_2a6fcaea-5ae6-4081-9758-cf4df636e1a9">FDA-Approved Patient Labeling</a></span></p>
<p><span class="Bold">Information for Patients</span></p>
<p>Information on the long term efficacy and safety of BETHKIS is limited. There is no information in patients with severe <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> (FEV<span class="Sub">1</span> &lt; 40% predicted).</p>
<p>Patients should be advised to complete a full 28-day course of BETHKIS, even if they are feeling better. After 28 days of therapy, patients should stop BETHKIS therapy for the next 28 days, and then resume therapy for the next 28 day on and 28 day off cycle.</p>
<p>For patients taking several different inhaled medications and/or performing chest physiotherapy, advise the patient regarding the order they should take the therapies. It is recommended that BETHKIS be taken last.</p>
<p>BETHKIS is to be used with the PARI LC PLUS reusable nebulizer and the PARI VIOS air compressor. Refer to the manufacturer’s instructions for care and use of the nebulizer and compressor.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3afc401e-d4f3-4efc-ac6f-ecff3f06e278"></a><a name="section-16.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span></h2>
<p class="First">Inform patients that <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, as measured by complaints of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, was reported by patients treated with tobramycin.  Physicians should consider an audiogram at baseline, particularly for patients at increased risk of auditory dysfunction.  </p>
<p>If a patient reports <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> or <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> during BETHKIS therapy, the physician should refer that patient for audiological assessment.</p>
<p>Patients should be reminded that vestibular toxicity may manifest as <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, or dizzines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_03befbe1-a8bb-42ae-9d88-e23929dbcd29"></a><a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></h2>
<p class="First">Inform patients that <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> can occur with inhalation of tobramycin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d66892cd-c9dc-45f5-8677-95d39a0c83b5"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Risks Associated with Aminoglycosides</h2>
<p class="First">Inform patients of adverse reactions associated with aminoglycosides such as <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and neuromuscular disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_46d3d906-85cb-4679-ba4f-75ba37d2c265"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Laboratory Tests</h2>
<p class="First">Inform patients of the need to monitor hearing, serum concentrations of tobramycin, or renal function as necessary during treatment with BETHKIS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cb65b99e-36fd-4f8d-9e93-7242456c3cd8"></a><a name="section-16.5"></a><p></p>
<h2>17.5 Pregnancy</h2>
<p class="First">Inform patients that aminoglycosides can cause fetal harm when administered to a pregnant woman.  Advise them to inform their doctor if they are pregnant, become pregnant, or plan to become pregnant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e08c3a66-4023-447f-9176-bb8532e834ea"></a><a name="section-16.6"></a><p></p>
<h2>17.6 Storage Instructions</h2>
<p class="First">You should store BETHKIS ampules in a refrigerator (36-46 °F or 2-8 °C). However, when you don’t have a refrigerator available (e.g., transporting your BETHKIS), you may store the foil pouches (opened or unopened) at room temperature (up to 77 °F/25 °C) for up to 28 days.</p>
<p>BETHKIS is light sensitive; unopened ampules should be returned to the foil pouch. Avoid exposing BETHKIS ampules to intense light. Unrefrigerated BETHKIS, which is normally colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, may darken with age; however, the color change does not indicate any change in the quality of the product.</p>
<p>You should not use BETHKIS if it is cloudy, if there are particles in the solution, or if it has been stored at room temperature for more than 28 days. You should not use BETHKIS beyond the expiration date stamped on the ampule.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9d208d87-08d4-4842-8324-9ea18235c220"></a><a name="section-16.7"></a><p></p>
<h2>17.7 Additional Information</h2>
<p class="First">Nebulizers and Compressors: 1-800-327-8632</p>
<p>BETHKIS: 1-888-661-9260</p>
<p>Rx Only<br>U.S. Patent 6,987,094.<br><br></p>
<p>Manufactured for Chiesi USA, Inc.  <br>by Catalent Pharma Solutions, LLC<br>Woodstock, Illinois 60098<br><br></p>
<p>DATE OF ISSUANCE 12/2014<br>© Chiesi USA, Inc. 2014 <br>Printed in USA</p>
<p>CTB-004-0514-03-SPL</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_2a6fcaea-5ae6-4081-9758-cf4df636e1a9"></a><a name="section-17"></a><p></p>
<h1>FDA-Approved Patient Labeling</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a1e02f95-a3a2-4fef-9306-4825ab824f74"></a><a name="section-17.1"></a><p></p>
<h2>Patient Information</h2>
<p class="First"><span class="Bold">BETHKIS<span class="Sup">® </span></span></p>
<p><span class="Bold">(BETH kiss)</span></p>
<p><span class="Bold">(tobramycin inhalation solution)</span></p>
<p>Read this Patient Information before you start taking BETHKIS and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is BETHKIS?</span></p>
<p>BETHKIS is a prescription medicine used to treat people with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> who have a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> called <span class="Italics">Pseudomonas aeruginosa</span>. BETHKIS contains an antibacterial medicine called tobramycin (an aminoglycoside).</p>
<p>It is not known if BETHKIS is safe and effective:</p>
<ul class="Disk">
<li>in children under 6 years of age </li>
<li>in people who have decreased lung volume or an FEV<span class="Sub">1</span> less than 40% of predicted</li>
<li>in people who are colonized with a bacterium called <span class="Italics">Burkholderia cepacia</span>
</li>
<li>when used for more than 3 cycles</li>
</ul>
<p><span class="Bold">Who should not take BETHKIS?</span></p>
<p>Do not take BETHKIS if you are allergic to tobramycin, any of the ingredients in BETHKIS, or to any other aminoglycoside antibacterial.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking BETHKIS?</span></p>
<p><span class="Bold">Before you take BETHKIS, tell your healthcare provider if you:</span></p>
<ul class="Disk">
<li>have or have had hearing problems (including noises in your ears)</li>
<li>have <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>have or have had kidney problems</li>
<li>have or have had problems with <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> such as <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or Parkinson’s disease</li>
<li>have or have had breathing problems such as <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, or <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span></li>
<li>have had an organ transplant</li>
<li>are pregnant or plan to become pregnant. </li>
<li>are breastfeeding or plan to breastfeed. It is not known if BETHKIS passes into your breast milk. </li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements.</p>
<p>Taking BETHKIS with certain other medicines can cause serious side effects.  </p>
<p>If you are taking BETHKIS, you should discuss with your healthcare provider if you should take:</p>
<ul class="Disk">
<li>other medicines that may harm your nervous system, kidneys, or hearing</li>
<li>“water pills? (diuretics) such as Edecrin (ethacrynic acid), Lasix (furosemide), or mannitol</li>
<li>urea</li>
</ul>
<p>Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.</p>
<p>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take BETHKIS?</span></p>
<ul class="Disk">
<li>See the step-by-step Instructions for Use at the end of this Patient Information leaflet about the right way to take BETHKIS.   </li>
<li>Take BETHKIS exactly as your healthcare provider tells you to. Ask your healthcare provider or pharmacist if you are not sure.  </li>
<li>The usual dose of BETHKIS for adults and children over 6 years of age is:<ul class="Circle"><li>1 ampule of BETHKIS inhaled by mouth in the morning and 1 ampule of BETHKIS inhaled by mouth in the evening using your hand-held PARI LC PLUS Reusable Nebulizer with a PARI Vios air compressor.</li></ul>
</li>
<li>Each dose of BETHKIS should take about 15 minutes to finish. </li>
<li>Each dose of BETHKIS should be taken as close to 12 hours apart as possible. </li>
<li>You should not take your dose of BETHKIS less than 6 hours apart.</li>
<li>After taking BETHKIS for 28 days, you should stop taking it and wait 28 days. After you have stopped taking BETHKIS for 28 days, you should start taking BETHKIS again for 28 days. It is important that you keep to the 28-day on, 28-day off cycle. </li>
<li>Do not mix BETHKIS with dornase alfa (Pulmozyme) in your nebulizer. </li>
<li>If you are taking other medicines inhaled through your mouth (bronchodilators), you should take them before you take BETHKIS.</li>
<li>If you take too much BETHKIS, tell your healthcare provider right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of BETHKIS?</span></p>
<p><span class="Bold">BETHKIS can cause serious side effects, including:</span></p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> or ringing in the ears (<span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>). Tell your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> or hear noises in your ears (such as ringing or hissing), or if you develop <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or difficulty with balance </li>
<li>worsening kidney problems (<span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>). Your healthcare provider may do a blood test and urine test to check how your kidneys are working while you are taking BETHKIS.</li>
<li>worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>. BETHKIS can cause <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> to get worse in people who already have problems with <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or Parkinson’s disease).</li>
<li>Tobramycin is in a class of drugs which may cause harm to an unborn baby.</li>
<li>severe breathing problems (<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>). Tell your healthcare provider right away if you get any of these symptoms of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> while taking BETHKIS:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> with <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> and <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>   </li>
</ul>
</li>
</ul>
<p><span class="Bold">The most common side effects of BETHKIS include:</span></p>
<ul class="Disk">
<li>worsening of lung problems or <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span></li>
<li>noisy breathing (<span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>)</li>
<li>abnormal red blood cell activity</li>
<li>changes in your voice (<span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>)</li>
</ul>
<p>Tell your healthcare provider about any side effect that bothers you or that does not go away.  </p>
<p>These are not all of the possible side effects of BETHKIS. For more information, ask your healthcare provider or pharmacist.<br>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA-1088.</p>
<p><span class="Bold">General information about the safe and effective use of BETHKIS.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use BETHKIS for a condition for which it was not prescribed. Do not give BETHKIS to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about BETHKIS. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about BETHKIS that is written for health professionals.</p>
<p>For more information, call 1-888-661-9260.</p>
<p><span class="Bold">What are the ingredients in BETHKIS?</span></p>
<p><span class="Bold">Active ingredient:</span>  tobramycin</p>
<p><span class="Bold">Inactive ingredients:</span> sodium chloride, sulfuric acid, and sodium hydroxide (for pH adjustment)<br><br></p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="LINK_61b6a317-3e9f-4127-9f4d-61660dcb2bc9"></a><a name="section-17.2"></a><p></p>
<h2>Instructions for Use</h2>
<p class="First"><span class="Bold">BETHKIS<span class="Sup">®</span></span></p>
<p><span class="Bold">(BETH kiss)</span></p>
<p><span class="Bold">(tobramycin inhalation solution)</span></p>
<p>Follow the instructions below for taking BETHKIS. If you have any questions, ask your healthcare provider or pharmacist.</p>
<p>BETHKIS is available as a 28-day supply containing 56 ampules including 14 foil pouches and as a 14-day supply containing 28 ampules including 7 foil pouches.  Each foil pouch contains 4 BETHKIS ampules. </p>
<p>Supplies you will need to take BETHKIS (See Figure A): </p>
<ul class="Disk">
<li>1 ampule of BETHKIS</li>
<li>PARI LC PLUS reusable nebulizer</li>
<li>PARI Vios compressor</li>
<li>tubing to connect the nebulizer and compressor</li>
<li>clean paper or cloth towels</li>
<li>nose clips (optional)</li>
</ul>
<div class="Figure"><img alt="BETHKIS supplies" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-3.jpg"></div>
<p>(Figure A)<br><br></p>
<p><span class="Bold">BETHKIS is used only in a PARI LC PLUS re-usable Nebulizer connected to a PARI LC PLUS Vios air compressor. Make sure you know how to use your nebulizer machine before you use it to breathe in BETHKIS.</span></p>
<p><span class="Bold">Do not</span> mix BETHKIS with other medicines in your nebulizer.</p>
<p>BETHKIS comes in a sealed foil pouch. Do not open a sealed pouch until you are ready to use a dose of BETHKIS. After opening the pouch, unused ready-to-use ampules should be returned to, and stored in, the pouch.  </p>
<p><span class="Bold">Getting ready:</span></p>
<ul class="Disk">
<li>Put your PARI LC PLUS Reusable Nebulizer Top and Bottom (Nebulizer Cup) Assembly, Inspiratory Valve Cap, Mouthpiece with Valve, and Tubing on a clean and dry surface. </li>
<li>Wash your hands with soap and water.</li>
</ul>
<p><span class="Bold">Preparing your BETHKIS dose:</span></p>
<p><span class="Bold">Step 1:</span> Open foil pouch. (See Figure B)</p>
<div class="Figure"><img alt="Opening BETHKIS foil pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-4.jpg"></div>
<p>(Figure B)<br><br></p>
<p><span class="Bold">Step 2:</span>  Separate 1 ampule by gently pulling apart at the bottom tabs (See Figure C) and use it right away. </p>
<div class="Figure"><img alt="Separating BETHKIS ampule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-5.jpg"></div>
<p>(Figure C)<br><br></p>
<p><span class="Bold">Step 3:</span>  Hold the bottom tab on the BETHKIS ampule with 1hand (See Figure D). With your other hand, hold the top of the ampule and twist off the top of the ampule (See Figure D).  </p>
<ul class="Disk"><li>Do not squeeze the ampule until you are ready to squeeze all the medicine into the Nebulizer Cup.</li></ul>
<div class="Figure"><img alt="Opening BETHKIS ampule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-6.jpg"></div>
<p>(Figure D)<br><br></p>
<p><span class="Bold">Step 4:</span>  Hold the Nebulizer Cup and twist off the Nebulizer Cup Top in a counter-clockwise direction (See Figure E). Set the Top aside on a clean, dry surface.</p>
<div class="Figure"><img alt="Opening the Nebulizer Cup" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-7.jpg"></div>
<p>(Figure E)<br><br></p>
<p><span class="Bold">Step 5:</span>  Squeeze all of the medicine from the ampule into the Nebulizer Cup (See Figure F).</p>
<div class="Figure"><img alt="Transferring BETHKIS medicine from the ampule into the Nebulizer Cup" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-8.jpg"></div>
<p>(Figure F)<br><br></p>
<p><span class="Bold">Step 6:</span>  Line up the semi-circle on the Nebulizer Cup Top with the Nebulizer Cup Outlet and twist on the Nebulizer Cup Top in a clock-wise direction until it is tight. (See Figure G).</p>
<div class="Figure"><img alt="Closing the Nebulizer Cup" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-9.jpg"></div>
<p>(Figure G)<br><br></p>
<p><span class="Bold">Step 7:</span>   Push the mouthpiece straight onto the Nebulizer Cup Outlet (See Figure H).</p>
<div class="Figure"><img alt="Mounting the mouthpiece onto the Nebulizer Cup Outlet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-10.jpg"></div>
<p>(Figure H)<br><br></p>
<p><span class="Bold">Step 8:</span>   Firmly push the Inspiratory Valve Cap straight down onto the Nebulizer Cup Top (See Figure I). The Inspiratory Valve Cap should fit tightly.</p>
<div class="Figure"><img alt="Mounting the Inspiratory Valve Cap onto the Nebulizer Cup Top" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-11.jpg"></div>
<p>(Figure I)<br><br></p>
<p><span class="Bold">Step 9:   </span>Connect 1 end of the tubing to the compressor air outlet. The tubing should fit tightly (See Figure J).</p>
<div class="Figure"><img alt="Connecting the tubing to the compressor air outlet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-12.jpg"></div>
<p>(Figure J)<br><br></p>
<p><span class="Bold">Step 10:</span> Plug your compressor plug into an electrical outlet (See Figure K).</p>
<div class="Figure"><img alt="Plugging the compressor plug into the electrical outlet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-13.jpg"></div>
<p>(Figure K)<br><br></p>
<p><span class="Bold">Step 11:</span> Hold the Nebulizer Cup upright and firmly push the free end of the tubing straight up onto the Air Intake on the bottom of the Nebulizer Cup (See Figure L). <span class="Bold">Make sure to keep the Nebulizer Cup upright.</span></p>
<div class="Figure"><img alt="Pushing the tubing onto the Air Intake of the Nebulizer Cup" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-14.jpg"></div>
<p>(Figure L)<br><br></p>
<p><span class="Bold">Giving your BETHKIS dose:</span></p>
<p><span class="Bold">Step 12:</span> Turn on the compressor (Figure M) and check the Mouthpiece. You should see a steady mist coming from the Mouthpiece (Figure N).  </p>
<ul class="Disk"><li>If you do not see a steady mist coming from the mouthpiece, check all tubing connections and make sure that the compressor is working the right way.</li></ul>
<div class="Figure"><img alt="Turning on the compressor" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-15.jpg"></div>
<p>(Figure M)<br><br></p>
<div class="Figure"><img alt="Checking a steady mist coming from the Mouthpiece" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-16.jpg"></div>
<p>(Figure N)<br><br></p>
<p><span class="Bold">Step 13:</span> Sit or stand in a comfortable, upright position that will let you breathe normally. Place the Mouthpiece between your teeth and on top of your tongue and breathe normally only through your mouth (See Figure O). </p>
<ul class="Disk"><li>Nose clips may help you breathe only through your mouth and not through your nose. </li></ul>
<div class="Figure"><img alt="Placing the Mouthpiece in the mouth" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-17.jpg"></div>
<p>(Figure O)<br><br></p>
<p><span class="Bold">Step 14:</span> Keep breathing in your BETHKIS dose for at least 15 minutes. You will know that you have received your full dose of medicine when you hear a “spitting noise? coming from the Mouthpiece for at least 1 minute and the Nebulizer Cup is empty.  </p>
<p><span class="Bold">After your BETHKIS Dose:</span></p>
<p><span class="Bold">Step 15:</span> Clean and disinfect your nebulizer (see manufacturer’s instructions).  <br><br></p>
<p><span class="Bold">Care and Use of Your PARI Vios<span class="Sup">®</span>Compressor</span></p>
<p><span class="Bold">Follow the manufacturer’s instructions for care and use of your compressor.</span></p>
<p><span class="Bold">How should I store BETHKIS?</span></p>
<ul class="Disk">
<li>Store BETHKIS in the refrigerator at 36°F to 46°F (2°C to 8°C) until needed.</li>
<li>BETHKIS may be stored at room temperature between 66°F to 77°F (20°C to 25°C) for up to 28 days.  </li>
<li>Do not use BETHKIS after the expiration date printed on the ampule.</li>
<li>Keep BETHKIS ampules in the foil pouch and away from light.  </li>
<li>Keep BETHKIS and all medications out of the reach of children.<br><br>
</li>
</ul>
<p>This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for Chiesi USA, Inc.  <br>by Catalent Pharma Solutions, LLC<br>Woodstock, Illinois 60098</p>
<p>All trademarks referenced herein are the property of their prospective owners.</p>
<p>Issued: 12/2014</p>
<p>CTB-006-0514-02-SPL</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_f1440f89-5481-4b1b-a479-96e4f9d5b551"></a><a name="section-18"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - 14 day</h1>
<p class="First"><img alt="Bethkis 28 ct carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-18.jpg"><p class="MultiMediaCaptionNotCentered">Bethkis 28 ct carton</p> </p>
<p><span class="Bold">NDC 10122-820-28</span></p>
<p><span class="Bold">Bethkis<span class="Sup">®</span></span></p>
<p><span class="Bold">(Tobramycin Inhalation Solution)</span></p>
<p><span class="Bold">300 mg/ 4 mL </span></p>
<p>For Oral Inhalation Only by Nebulizer</p>
<p>Single Use Only, Discard Each Ampule After One Use</p>
<p><span class="Bold">Contents: </span>Each single-use ampule delivers 4 mL of solution containing<br>300 mg of Tobramycin and 18 mg of Sodium Chloride in Water for Injection.<br><span class="Bold">Usual Dose: </span>See package insert for details.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Storage: Store in a Refrigerator </span><span class="Bold">at 2°C to 8°C (36°F to 46°F). </span></p>
<p><span class="Bold">Bethkis<span class="Sup">® </span>is light sensitive; <br>unopened ampules should be returned to the foil pouch.</span></p>
<p><span class="Bold">Each carton contains 28 Single-Use Ampules (14-Day Supply)</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_edeeff7c-da50-4c64-b558-b00fa26c3276"></a><a name="section-19"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - carton label</h1>
<div class="Figure">
<img alt="Bethkis 56 ct carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-19.jpg"><p class="MultiMediaCaption">Bethkis 56 ct carton</p>
</div>
<p class="First"><span class="Bold">NDC 10122-820-56</span></p>
<p><span class="Bold">Bethkis<span class="Sup">®</span></span></p>
<p><span class="Bold">(Tobramycin Inhalation Solution)</span></p>
<p><span class="Bold">300 mg/ 4 mL </span></p>
<p>For Oral Inhalation Only by Nebulizer</p>
<p>Single Use Only, Discard Each Ampule After One Use</p>
<p><span class="Bold">Contents: </span>Each single-use ampule delivers 4 mL of solution containing<br>300 mg of Tobramycin and 18 mg of Sodium Chloride in Water for Injection.<br><span class="Bold">Usual Dose: </span>See package insert for details.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Storage: Store in a Refrigerator </span><span class="Bold">at 2°C to 8°C (36°F to 46°F). </span></p>
<p><span class="Bold">Bethkis<span class="Sup">® </span>is light sensitive; <br>unopened ampules should be returned to the foil pouch.</span></p>
<p><span class="Bold">Each carton contains 56 Single-Use Ampules (28-Day Supply)</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_93dd4277-efdd-444d-bd08-f92c37f8effa"></a><a name="section-20"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - pouch label</h1>
<div class="Figure">
<img alt="Bethkis foil pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-20.jpg"><p class="MultiMediaCaption">Bethkis foil pouch</p>
</div>
<p class="First"><span class="Bold">NDC 10122-820-04</span></p>
<p><span class="Bold">Bethkis<span class="Sup">®</span></span></p>
<p><span class="Bold">Tobramycin Inhalation Solution </span></p>
<p><span class="Bold">300 mg/ 4 mL Ampule</span></p>
<p>For Oral Inhalation Only by Nebulizer</p>
<p>Single Use Only. Discard Each Ampule After One Use.</p>
<p>Each foil pouch contains 4 ampules.</p>
<p><span class="Bold">Storage: Store in a Refrigerator </span><span class="Bold">at 2°C to 8°C (36°F to 46°F). Protect from Intense Light.</span></p>
<p><span class="Bold">Bethkis<span class="Sup">® </span>is light sensitive; unopened ampules should be returned to the foil pouch.</span></p>
<p><span class="Bold">Contents: </span>Each single-use ampule delivers 4 mL<br>of solution containing 300 mg of Tobramycin<br>and 18 mg of sodium chloride in Water for Injection.</p>
<p><span class="Bold">Usual Dose: </span>See package insert for details.</p>
<p>Contains No Preservatives</p>
<p>Rx Only</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_121e73a8-6d16-46df-a955-a07b38ff6882"></a><a name="section-21"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - ampule label</h1>
<div class="Figure"><img alt="Bethkis® (Tobramycin Inhalation Solution) 300 mg / 4 mL Ampule Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223&amp;name=bethkis-21.jpg"></div>
<p class="First">Bethkis<span class="Sup">®</span> 300 mg/ 4 mL</p>
<p>Tobramycin Inhalation Solution</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BETHKIS 		
					</strong><br><span class="contentTableReg">tobramycin solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10122-820</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TOBRAMYCIN</strong> (TOBRAMYCIN) </td>
<td class="formItem">TOBRAMYCIN</td>
<td class="formItem">300 mg  in 4 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10122-820-28</td>
<td class="formItem">7  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:10122-820-56</td>
<td class="formItem">14  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">4  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201820</td>
<td class="formItem">04/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Chiesi USA, Inc.
							(088084228)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Chiesi USA, Inc. (088084228)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>95487c32-8216-472a-a81e-eded086463f8</div>
<div>Set id: 1cd3d47b-025f-4705-9daf-cf07725ec223</div>
<div>Version: 6</div>
<div>Effective Time: 20141209</div>
</div>
</div> <div class="DistributorName">Chiesi USA, Inc.</div></p>
</body></html>
